Currently out of the existing stock ratings of Chris Schott, 7 are a SELL (4.38%), 37 are a HOLD (23.13%), 116 are a BUY (72.5%).

Chris Schott

Work Performance Price Targets & Ratings Chart

Analyst Chris Schott works with a stock forecast success ratio of 44.38% fulfilled within 262.93 days on average. Previously, Chris Schott worked at JPMORGAN.

Chris Schott’s has documented 334 price targets and ratings displayed on 27 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PRGO, Perrigo Company PLC at 28-Feb-2024.

Wall Street Analyst Chris Schott

Analyst best performing recommendations are on EQRX (EQRX).
The best stock recommendation documented was for EQRX (EQRX) at 8/16/2022. The price target of $5.5 was fulfilled within 3 days with a profit of $0.67 (13.87%) receiving and performance score of 46.24.

Average potential price target upside

of $128.17 (16.68%) on REGN (REGENERON PHARMACEUTICALS).
of $93.68 (22.78%) on IDXX (IDEXX LABORATORIES).
of $64.42 (47.96%) on AGN (ALLERGAN PLC).

ABBV AbbVie BHC Bausch Health Companies BMY Bristol-Myers Squibb Company HZNP Horizon Pharma PLC IDXX IDEXX Laboratories JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany PFE Pfizer TEVA Teva Pharma Industries Ltd ADR ELAN Elanco Animal Health HSKA Heska MYL Viatris AGN Allergan plc CHRS Coherus BioSciences MNK Mallinckrodt plc RPRX Royalty Pharma Plc VTRS Viatris EQRX EQRx ZTS Zoetis ENDP Endo International PLC PRGO Perrigo Company PLC REGN Regeneron Pharmaceuticals TXMD TherapeuticsMD KALA Kala Pharmaceuticals OGN Organon PCRX Pacira Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Carter Gould (BARCLAYS)